Numerous studies by our group and others confirm blunted allogeneic responses by umbilical cord blood (UCB) graft CD4 þ T-cells. 1 This may be attributable in part to dramatically reduced NFAT1 protein without corresponding mRNA discrepancies. 2 We have previously shown that microRNA-184 (miR-184) mediates NFAT1 translational regulation in UCB CD4 þ T-cells. 3 In humans, miR-184 resides within region 25.1 on the q-arm of chromosome 15 and exhibits characteristics that are uncommon to many other intergenic miRNA species. Specifically, its transcript is comparatively small (84 bp) and is not encoded near other clustered miRNAs.
A recent report has identified DNA methylation patterns and the methyl-CpG binding protein MeCP2 during polarization and imprinting as relevant to miR-184 expression in murine brain. 4 MeCP2 is hypothesized to bind differentially to hemimethylated regions or specific CpG sites, resulting in transcriptional repression via recruitment of histone-modifying enzymes or other mechanisms. 5 Although the region containing miR-184 on murine chromosome 9E3.1 exhibits a very high degree of sequence homology to the miR-184 region on human 15q25.1, little is known about regulation of miR-184 expression in human T-lymphocytes. Here we identify the epigenetic mechanisms underlying miR-184 regulation in human CD4
þ T-cells. Previous work by this group demonstrated increased NFAT1 protein expression in UCB CD4
þ T-lymphocytes treated with interferon g (IFNg) during stimulation. 6 Therefore, utilizing this previous observation, we sought to determine the mechanisms contributing to the 450-fold higher miR-184 expression in UCB CD4 þ T-lymphocytes and resultant low NFAT1 protein expression. UCB mononuclear cells were stimulated in vitro with aCD3/ CD28 with and without 1000 U/ml recombinant IFNg, and CD4 In light of this response to IFNg treatment, the miR-184 genomic region was examined for STAT binding; however, none was observed in crosslinking chromatin immunoprecipitation (X-ChIP) experiments (data not shown). Analysis did reveal a small CpG island directly upstream of the miR-184 site and many additional CpG sites both upstream and downstream ( Figure 2a) . CpG methylation at these sites was evaluated by PCR following sodium bisulfite treatment of genomic DNA isolated from UCB and adult blood (AB) CD4
þ T-cells. PCR products from nine nested primer sets flanking 32 specific CpG sites were purified, cloned, sequenced, and C-G to A-T base pair conversions were scored as unmethylated CpG sites. miR-184 regions from both UCB ( Figure 2b ) and AB ( Figure 2c ) CD4 þ T-cells were found to be similarly demethylated in the B600-bp region preceding the miR-184 site, as well as similarly more methylated upstream of that region. This upstream hemi-methylation pattern was noted to be maintained when UCB CD4
þ T-cells were treated with IFNg during primary stimulation (Figure 3c ). Based on these data, it may be hypothesized that if miR-184 is differentially regulated by a demethylated region, it would be significantly more distal to the miR-184 promoter than is observed in our analyses.
Based on the similarity of our findings with other reports implicating the binding of MeCP2 to similarly hemi-methylated regions in regulating miR-184 expression, 4 X-ChIP was performed with immunoprecipitation (IP) antibody directed against MeCP2 and primers directed against similar nested regions to those analysed in Letters to the Editor (Figure 3a) . MeCP2 binding in UCB was also increased coincidental with the previously observed increase in CpG DNA methylation upon treatment with IFNg during stimulation (Figure 3b ), both suggesting a repressive role for MeCP2 binding to the miR-184 region.
To confirm the role of DNA methylation and methyl-CpG DNA-binding proteins in regulating expression of miR-184, AB CD4 þ T-cells were treated with the nucleotide analogue 5-aza-2 0 -deoxycytidine (5-azaD). This analogue incorporates in place of cytosine and renders the site inaccessible to DNA methyltransferase enzymes, mimicking demethylated CpG DNA. 5-azaD was incorporated during interleukin (IL)2-mediated expansion over 5 days as described (Materials and methods available as Supplementary Materials online), and miR-184 quantity was analysed in UCB CD4 þ T-cells by qRT-PCR. Increased miR-184 expression was measured by day 4-5 ( Figure 4a ) with no significant change in NFATc2 (NFAT1-encoding) mRNA quantity ( Figure 4b ). As we had not previously observed changes in NFAT1 protein quantity in response to IL2 expansion alone, we anticipated that any effects IL2 would have on the miR-184 site would be insufficient to influence miR-184 expression. However, IL2-mediated alterations in methyl-CpG protein binding patterns cannot be fully ruled out. X-ChIP analysis did confirm loss of MeCP2 binding in these treated cells (Figure 4c ). Taken together, these observations indicate that reduced CpG DNA methylation promotes miR-184 expression via release of MeCP2 in UCB CD4 þ T-cells. As anticipated, the observed increase in miR-184 coincided with a decrease in Letters to the Editor NFAT1 protein as measured by western blot (Figure 4d ). To further confirm these observations, isolated UCB CD4 þ T-cells were pretreated for 48 h with 5-azaD before CD3/28 antigen stimulation in the presence of IFNg (Supplementary Figure S1) . Although not statistically significant in this analysis, the trend observed in miR-184 quantity suggested that inhibiting methylation with 5-azaD may interfere with the observed IFNgmediated miR-184 downregulation in UCB CD4
þ T-cells. DNA methylation and binding of methyl-binding domain (MBD)-containing proteins is commonly associated with formation of heterochromatin, in part characterized by di-or trimethylation at histone 3-lysine 9 (H3K9; 7 ). X-ChIP was performed using antibody directed against the histone modification H3K9me2/3 and results confirm that the addition of the H3K9me2/3 modification near the miR-184 genomic site in AB CD4
þ T-cells occurs at a higher incidence than observed at baseline ( Figure 5, left) . Inhibition of DNA methylation via 5-azaD treatment did not completely eliminate H3K9me2/3 modification near the miR-184 region, indicating the possibility for a redundancy mechanism for chromatin remodelling independent of CpG methylation and MeCP2 binding. An additional increase in H3K9me2/3 modification in IFNg-treated and stimulated UCB CD4 þ T-cells over baseline was also noted ( Figure 5, right) . Owing to the coincidence of this modification under conditions where MeCP2 binding is shown to be increased and miR-184 expression reduced, we hypothesize MeCP2 binding comprises a key step in epigenetic control of miR-184. The degree to which other MBD proteins may display redundancy at the miR-184 site, and the potential synergism of histone-modifying drugs such as HDACs with 5-azaD on miR-184 expression are compelling questions for future investigations.
This work is a continuation of our previous work on miR-184 and NFAT1 3 and provides new insight into epigenetic regulation of the miR-184 locus in human CD4
þ T-cells. miR-184 expression is susceptible to alteration by CD3/28 antigen stimulation in the presence of exogenous IFNg. Differential binding of methyl-DNA-binding proteins including MeCP2, as well as alterations in histone modifications, appears to underlie the differences in miR-184 expression in the absence of significant DNA methylation differences between CD4
þ T-cells of UCB and AB origin. In general, increased binding of MeCP2 to the miR-184 locus coincided with lower expression of miR-184 in both AB CD4 þ T-cells as well as UCB CD4 þ treated with IFNg during CD3/28 antigen stimulation, implying a negative regulatory role for MeCP2. Further, we suggest an additional mechanism by which demethylating agents may contribute to T-lymphocyte differentiation and activation, via activating transcription of miRNAs targeting critical immunomodulatory proteins.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Figure 5 X-ChIP was performed on UCB and AB CD4 þ samples for di-/tri-methylated histone 3-lysine 9 (H3K9me2/3) as described. Sequential bars for each sample indicate the quantifications obtained sequential primer sets.
